SCHEMBL25208076

SCHEMBL25208076

CCOc1cc(/C=C/C(=O)c2ccc(SC)cc2)ccc1O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.68
▸ LMNA P02545 5/20 0.68
▸ KDM4E B2RXH2 2/20 0.68
▸ POLB P06746 2/20 0.68
▸ NPSR1 Q6W5P4 1/20 0.68
▸ TOP2A P11388 1/20 0.63
▸ PDE4A P27815 1/20 0.61
▸ PDE4B Q07343 1/20 0.61
▸ PDE4C Q08493 1/20 0.61
▸ PDE4D Q08499 1/20 0.61
▸ RAB9A P51151 3/20 0.59
▸ MEN1 O00255 2/20 0.59
▸ ALDH1A1 P00352 2/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ GAA P10253 1/20 0.59
▸ CASP3 P42574 1/20 0.59
▸ SENP8 Q96LD8 1/20 0.59
▸ SENP7 Q9BQF6 1/20 0.59
▸ SENP6 Q9GZR1 1/20 0.59
▸ NPC1 O15118 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30383392 1.00 MAPT (0.68) MAPTLMNAKDM4EPOLBNPSR1
SCHEMBL11342200 0.88 LMNA (0.69) MAPTLMNAKDM4EPOLBTOP2A
SCHEMBL11342203 0.88 LMNA (0.69) MAPTLMNAKDM4EPOLBTOP2A
SCHEMBL30384277 0.86 CXCL12 (0.74) MAPTLMNAKDM4EPOLBTOP2A
SCHEMBL28606019 0.86 CXCL12 (0.74) CXCL12
SCHEMBL30384133 0.86 CXCL12 (0.74) MAPTLMNAKDM4EPOLBTOP2A
SCHEMBL25216640 0.86 CXCL12 (0.74) MAPTLMNAKDM4EPOLBTOP2A
SCHEMBL25221493 0.86 MAPT (0.73) MAPTLMNAKDM4EPOLBNPSR1
SCHEMBL25219819 0.86 CXCL12 (0.74) MAPTLMNAKDM4EPOLBTOP2A
SCHEMBL30383313 0.86 MAPT (0.73) MAPTLMNAKDM4EPOLBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 — — US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 — — US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 — — WO disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 — — US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAPT 3297/4885LMNA 1180/4885KDM4E 1732/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885LMNA 1817/4885KDM4E 2652/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885LMNA 1817/4885KDM4E 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback